+Follow
Ah Hao
No personal profile
139
Follow
0
Followers
0
Topic
0
Badge
Posts
Hot
Ah Hao
2022-01-10
good
My 3 Favorite Stocks Right Now
Ah Hao
2021-08-12
Good
Syrida Medical-B will launch its IPO today, and the admission fee is about HK $24,039.83
Ah Hao
2022-11-28
$Sea Ltd(SE)$
Ah Hao
2022-12-07
$TLT 20221216 106.0 CALL$
$TLT 20221216 106.0 CALL$
Ah Hao
2021-09-23
Hi Hi
Survey: Investors think it's time to take a conservative strategy in the stock market
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3579760220696360","uuid":"3579760220696360","gmtCreate":1616668597679,"gmtModify":1691120229333,"name":"Ah Hao","pinyin":"ahhaoahhao","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/ab98bd75f814e47f112190452ed8a673","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":139,"tweetSize":42,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":21,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.05.04","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.03.20","exceedPercentage":"93.68%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.02.23","exceedPercentage":"93.80%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":3,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":9920959334,"gmtCreate":1670423630628,"gmtModify":1676538364825,"author":{"id":"3579760220696360","authorId":"3579760220696360","name":"Ah Hao","avatar":"https://static.tigerbbs.com/ab98bd75f814e47f112190452ed8a673","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3579760220696360","idStr":"3579760220696360"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/OPT/TLT 20221216 106.0 CALL\">$TLT 20221216 106.0 CALL$ </a><a href=\"https://ttm.financial/OPT/TLT 20221216 106.0 CALL\">$TLT 20221216 106.0 CALL$ </a> ","listText":"<a href=\"https://ttm.financial/OPT/TLT 20221216 106.0 CALL\">$TLT 20221216 106.0 CALL$ </a><a href=\"https://ttm.financial/OPT/TLT 20221216 106.0 CALL\">$TLT 20221216 106.0 CALL$ </a> ","text":"$TLT 20221216 106.0 CALL$ $TLT 20221216 106.0 CALL$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9920959334","isVote":1,"tweetType":1,"viewCount":1375,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9966718672,"gmtCreate":1669643436997,"gmtModify":1676538217670,"author":{"id":"3579760220696360","authorId":"3579760220696360","name":"Ah Hao","avatar":"https://static.tigerbbs.com/ab98bd75f814e47f112190452ed8a673","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3579760220696360","idStr":"3579760220696360"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/SE\">$Sea Ltd(SE)$ </a><v-v data-views=\"1\"></v-v>","listText":"<a href=\"https://ttm.financial/S/SE\">$Sea Ltd(SE)$ </a><v-v data-views=\"1\"></v-v>","text":"$Sea Ltd(SE)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9966718672","isVote":1,"tweetType":1,"viewCount":1833,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9006233508,"gmtCreate":1641749420496,"gmtModify":1676533644495,"author":{"id":"3579760220696360","authorId":"3579760220696360","name":"Ah Hao","avatar":"https://static.tigerbbs.com/ab98bd75f814e47f112190452ed8a673","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3579760220696360","idStr":"3579760220696360"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006233508","repostId":"2201249471","repostType":2,"repost":{"id":"2201249471","kind":"highlight","pubTimestamp":1641691426,"share":"https://ttm.financial/m/news/2201249471?lang=en_US&edition=fundamental","pubTime":"2022-01-09 09:23","market":"us","language":"en","title":"My 3 Favorite Stocks Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2201249471","media":"Motley Fool","summary":"These glaring deals from the small and mid-cap arena could be substantial long-term winners.","content":"<div>\n<p>Unless a portfolio is constructed entirely of mega-cap stocks, it's probably seeing more red than green days lately. The market can seem like a popularity contest, and small and mid-cap growth stocks ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/08/my-3-favorite-stocks-right-now/\">Source Link</a>\n\n</div>\n","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>My 3 Favorite Stocks Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMy 3 Favorite Stocks Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-09 09:23 GMT+8 <a href=https://www.fool.com/investing/2022/01/08/my-3-favorite-stocks-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Unless a portfolio is constructed entirely of mega-cap stocks, it's probably seeing more red than green days lately. The market can seem like a popularity contest, and small and mid-cap growth stocks ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/08/my-3-favorite-stocks-right-now/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4554":"元宇宙及AR概念","AFRM":"Affirm Holdings, Inc.","SE":"Sea Ltd","BK4551":"寇图资本持仓","BK4566":"资本集团","BK4528":"SaaS概念","BK4097":"系统软件","CRWD":"CrowdStrike Holdings, Inc.","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","BK4503":"景林资产持仓","BK4560":"网络安全概念","BK4532":"文艺复兴科技持仓","BK4106":"数据处理与外包服务","BK4085":"互动家庭娱乐"},"source_url":"https://www.fool.com/investing/2022/01/08/my-3-favorite-stocks-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201249471","content_text":"Unless a portfolio is constructed entirely of mega-cap stocks, it's probably seeing more red than green days lately. The market can seem like a popularity contest, and small and mid-cap growth stocks are not cool right now.But it would help if investors looked at the positives in all of this selling pressure. With so many stocks selling off, it's a great time to buy stocks at great prices. The market has hammered these three stocks recently, but they have a long-term upside that could make them huge winners down the road.1. Affirm HoldingsBuy now, pay later (BNPL) took 2021 by storm, growing roughly fourfold to $100 billion this past year. Experts think it could expand to 15 times its current volume by 2025. The simple structure of fixed installments that often carry zero interest is rapidly gaining popularity over traditional consumer credit cards.Image source: Getty Images.Affirm (NASDAQ:AFRM) is one of the leading BNPL companies. It works with its retail partners to offer installment payment plans on products. Users can shop right from the Affirm app and use Affirm's payment tools when checking out. Retailers have an incentive to use BNPL because it increases order size and customer loyalty. Shoppers can fit more into their carts, and they like the simple financing. In other words, it has become a sales tool for retailers.Affirm has secured numerous partnerships with leading e-commerce merchants, including Amazon, Walmart, Shopify, and Target. In its first quarter of 2022 (period ending Sept. 30, 2021), the company reported that its merchant partnerships had increased 1,468% year over year to 102,200. Affirm hasn't even commented on its guidance since announcing the Amazon partnership, so it seems reasonable that its 84% year-over-year merchandise volume growth in 2022 Q1 could continue from here.Despite this good news, the stock has been caught up in a broader market tech sell-off and has fallen more than 50% from its highs. At $80 per share, the stock almost trades as low as before Affirm announced the Amazon partnership.Affirm isn't profitable, but it's spending heavily on building new products and services; it has ambitions of becoming a broader financial services company, bringing a finance super-app and debit card to market over the coming quarters. As these products launch and revenue grows, investors should look for the business to begin heading toward a positive operating income.2. Crowdstrike HoldingsThe world is becoming increasingly digital at a rapid pace. Yet, consumers' and businesses' tools to protect themselves from digital threats are largely still behind the times. Someone could do a simple internet search and find countless instances of breached, hacked, or compromised companies.CrowdStrike (NASDAQ:CRWD) is a cloud-based leader in endpoint security, in which a network protects user devices like computers and mobile devices from digital threats. In the old days, people would download antivirus software, receive occasional updates from the security company which ultimately would tell the antivirus program what threats looked like.CrowdStrike's Falcon platform delivers various protections through the cloud, giving the software real-time information and updates. Devices connected on Falcon are linked, similar to a massive network. If an attack happens on one device, the system learns and instantly shares this information with the other devices throughout the network. As more devices are connected, it creates a network effect, and the Falcon platform learns more, faster.The stock has had a great run since COVID-19 started but has since pulled back roughly 40% from its highs. CrowdStrike grew subscription revenue 67% year over year in its most recent quarter, the third quarter of 2022 (Oct. 31, 2021), to $357 million. The company is reporting net losses but is growing its free cash flow; it was $123.5 million in 2022 Q3, a 62% year-over-year increase. Free cash flow is a positive step toward posting a profit, so investors should look for cash flow to keep growing, and net losses to shrink over the coming quarters.3. Sea LimitedThe population in Southeast Asia is friendly toward technology; the region boasts a population of roughly 670 million, and half are under age 30. They also tend to spend eight hours on the internet each day, more than the global average. In other words, they are a great target market for digital businesses.Sea Limited (NYSE:SE) is an internet company with various digital business segments, including e-commerce, mobile gaming, and financial services. Garena, its gaming business, is driven by FreeFire, one of the most popular mobile games in the world. It's also the most profitable part of the company, responsible for all of Sea's adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA).The company uses these profits to expand other parts of its business heavily. For example, Sea has taken its e-commerce business, Shopee, to other regions in the world, including Latin America, Europe, and India. The company is aggressively pumping its cash back into the business to pay for the employees, buildings, and resources needed for these new markets, so the overall business is losing money right now. However, I expect that the spending eventually levels off, and revenue growth will outpace the money Sea spends, pushing the company toward profits. Investors will want to pay attention to whether losses grow or shrink in future quarters.Sea's total revenue grew 122% year over year in its most recent quarter, 2021 Q3, and there is reason to believe that rapid growth can continue for years to come. E-commerce, gaming, and fintech are all massive addressable markets, and Sea's ambition to attack them at a global scale gives the business a virtually endless runway for growth. The stock is 50% off its highs, so investors with the patience to hold for the long term could be scooping up shares at a nice discount.","news_type":1,"symbols_score_info":{"AFRM":1,"SE":1,"CRWD":1}},"isVote":1,"tweetType":1,"viewCount":2181,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":863015628,"gmtCreate":1632331437664,"gmtModify":1676530755591,"author":{"id":"3579760220696360","authorId":"3579760220696360","name":"Ah Hao","avatar":"https://static.tigerbbs.com/ab98bd75f814e47f112190452ed8a673","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3579760220696360","idStr":"3579760220696360"},"themes":[],"htmlText":"Hi Hi","listText":"Hi Hi","text":"Hi Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/863015628","repostId":"2169665276","repostType":2,"repost":{"id":"2169665276","kind":"news","pubTimestamp":1632327780,"share":"https://ttm.financial/m/news/2169665276?lang=en_US&edition=fundamental","pubTime":"2021-09-23 00:23","market":"us","language":"zh","title":"Survey: Investors think it's time to take a conservative strategy in the stock market","url":"https://stock-news.laohu8.com/highlight/detail?id=2169665276","media":"新浪美股","summary":"据媒体最新调查，华尔街投资者们认为，随着本月担忧继情绪续加剧，是时候将一些风险排除在外了。 媒体本周对大约400名首席投资官、股票策略师、投资组合经理和媒体撰稿人进行了调查。 尽管投资者目前对市场持更为谨慎的看法，但他们仍认为未来12个月股市可能会走高。约一半的受访者表示，标普500指数在未来12个月内将上涨5%以上。","content":"<p>According to the latest media survey, Wall Street investors believe that as concerns continue to intensify this month, it is time to exclude some risks.</p><p>The media surveyed roughly 400 chief investment officers, equity strategists, portfolio managers and media writers this week. When asked what market risk they are willing to accept for themselves and their clients, more than three-quarters of respondents said it's time to be very conservative in the stock market.<img src=\"https://static.tigerbbs.com/65778cdcafa625d17574b193f4c4294b\" tg-width=\"550\" tg-height=\"195\" referrerpolicy=\"no-referrer\"></p><p>While investors are currently taking a more cautious view of the market, they still think stocks are likely to move higher over the next 12 months. About half of respondents said the S&P 500 would rise more than 5% over the next 12 months. Forty-four percent said it would be essentially flat and five percent said they expect a decline next year.</p><p><img src=\"https://static.tigerbbs.com/0d55b716f44344dafd3c388b94d84c5a\" tg-width=\"550\" tg-height=\"244\" referrerpolicy=\"no-referrer\">Following this week's pullback, the S&P 500 is down about 4.2% from its all-time high set in early September. Many market participants believe that the market is experiencing seasonal weakness.</p><p>\"Market sentiment appears to have shifted in favor of the bears over the past few weeks,\" said Brian Price, head of investment management at Commonwealth Financial Network. \"After a relatively quiet summer, market participants appear to be looking to dampen this year's rally.\"</p><p>Some prominent strategists stick to bullish. Fundstrat co-founder Tom Lee sees Monday's stock market plunge as a buying opportunity for investors.<a href=\"https://laohu8.com/S/JPM\">JPMorgan Chase</a>Strategist Marko Kolanovic also called the sell-off excessive.</p><p>However, one of Wall Street's biggest shorts-<a href=\"https://laohu8.com/S/MS\">Morgan Stanley</a>Mike Wilson of the S&P 500 sees a 20% pullback as some economic indicators begin to deteriorate, which is a \"destructive\" scenario.</p><p>The findings show that the best strategy right now for yield-focused investors is private credit. Only 2% of respondents believe that U.S. Treasury Bond can provide attractive benefits.</p><p>Government bonds are rapidly becoming one of the most disgusting asset classes, as their safe-haven appeal weakens during the economic recovery. Bill Gross, the \"old debt king\", recently called the U.S. Treasury Bond rubbish, saying that the yield of 10-year Treasury Bond in the next 12 months will be around 2%, which is equivalent to a price loss of 4%-5% and a negative return of 2.5%-3%.</p>","source":"sina","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Survey: Investors think it's time to take a conservative strategy in the stock market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSurvey: Investors think it's time to take a conservative strategy in the stock market\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">新浪美股</strong><span class=\"h-time small\">2021-09-23 00:23</span>\n</p>\n</h4>\n</header>\n<article>\n<p>According to the latest media survey, Wall Street investors believe that as concerns continue to intensify this month, it is time to exclude some risks.</p><p>The media surveyed roughly 400 chief investment officers, equity strategists, portfolio managers and media writers this week. When asked what market risk they are willing to accept for themselves and their clients, more than three-quarters of respondents said it's time to be very conservative in the stock market.<img src=\"https://static.tigerbbs.com/65778cdcafa625d17574b193f4c4294b\" tg-width=\"550\" tg-height=\"195\" referrerpolicy=\"no-referrer\"></p><p>While investors are currently taking a more cautious view of the market, they still think stocks are likely to move higher over the next 12 months. About half of respondents said the S&P 500 would rise more than 5% over the next 12 months. Forty-four percent said it would be essentially flat and five percent said they expect a decline next year.</p><p><img src=\"https://static.tigerbbs.com/0d55b716f44344dafd3c388b94d84c5a\" tg-width=\"550\" tg-height=\"244\" referrerpolicy=\"no-referrer\">Following this week's pullback, the S&P 500 is down about 4.2% from its all-time high set in early September. Many market participants believe that the market is experiencing seasonal weakness.</p><p>\"Market sentiment appears to have shifted in favor of the bears over the past few weeks,\" said Brian Price, head of investment management at Commonwealth Financial Network. \"After a relatively quiet summer, market participants appear to be looking to dampen this year's rally.\"</p><p>Some prominent strategists stick to bullish. Fundstrat co-founder Tom Lee sees Monday's stock market plunge as a buying opportunity for investors.<a href=\"https://laohu8.com/S/JPM\">JPMorgan Chase</a>Strategist Marko Kolanovic also called the sell-off excessive.</p><p>However, one of Wall Street's biggest shorts-<a href=\"https://laohu8.com/S/MS\">Morgan Stanley</a>Mike Wilson of the S&P 500 sees a 20% pullback as some economic indicators begin to deteriorate, which is a \"destructive\" scenario.</p><p>The findings show that the best strategy right now for yield-focused investors is private credit. Only 2% of respondents believe that U.S. Treasury Bond can provide attractive benefits.</p><p>Government bonds are rapidly becoming one of the most disgusting asset classes, as their safe-haven appeal weakens during the economic recovery. Bill Gross, the \"old debt king\", recently called the U.S. Treasury Bond rubbish, saying that the yield of 10-year Treasury Bond in the next 12 months will be around 2%, which is equivalent to a price loss of 4%-5% and a negative return of 2.5%-3%.</p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://finance.sina.com.cn/stock/usstock/c/2021-09-23/doc-iktzscyx5742473.shtml\">新浪美股</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/ee61dd9fe3e53070a1d0efed49b773f5","relate_stocks":{"161125":"标普500","513500":"标普500ETF",".SPX":"S&P 500 Index","UPRO":"三倍做多标普500ETF-ProShares","SH":"做空标普500-Proshares","SDS":"两倍做空标普500 ETF-ProShares","OEX":"标普100","IVV":"标普500ETF-iShares","SPXU":"三倍做空标普500ETF-ProShares","OEF":"标普100指数ETF-iShares","SPY":"标普500ETF","SSO":"2倍做多标普500ETF-ProShares"},"source_url":"https://finance.sina.com.cn/stock/usstock/c/2021-09-23/doc-iktzscyx5742473.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","article_id":"2169665276","content_text":"据媒体最新调查，华尔街投资者们认为，随着本月担忧继情绪续加剧，是时候将一些风险排除在外了。\n媒体本周对大约400名首席投资官、股票策略师、投资组合经理和媒体撰稿人进行了调查。当被问及他们愿意为自己和客户接受什么样的市场风险时，超过四分之三的受访者表示，现在是在股市中非常保守的时候了。\n尽管投资者目前对市场持更为谨慎的看法，但他们仍认为未来12个月股市可能会走高。约一半的受访者表示，标普500指数在未来12个月内将上涨5%以上。44%的人表示将基本持平，5%的人表示预计明年会下跌。\n在本周回调之后，标普500指数较9月初创下的历史高点下跌了约4.2%。许多市场人士认为，市场正在经历季节性疲软。\n“过去几周市场情绪似乎发生了有利于空头的变化，”Commonwealth Financial Network投资管理主管Brian Price表示。 “在一个相对平静的夏季之后，市场参与者似乎希望减弱今年的涨势。”\n一些著名的策略师坚持看涨。Fundstrat联合创始人Tom Lee认为，周一股市的暴跌对投资者来说是一个买入机会。摩根大通策略师Marko Kolanovic也称此次抛售过度。\n然而，华尔街最大的空头之一——摩根士丹利的Mike Wilson认为，随着一些经济指标开始恶化，标普500指数将出现20%的回调，这是一种“破坏性”的情景。\n调查结果显示，对于关注收益率的投资者来说，目前最好的策略是私人信贷。只有2%的受访者认为美国国债可以提供有吸引力的收益。\n政府债券正迅速成为最令人厌恶的资产类别之一，因在经济复苏期间其避险吸引力减弱。“老债王”比尔-格罗斯（Bill Gross）近期称美国国债为垃圾，称未来12个月10年期国债收益率将在2%左右，这相当于4%-5%的价格损失和2.5%-3%的负回报。","news_type":1,"symbols_score_info":{"161125":0.9,"513500":0.9,"SPY":0.9,"SSO":0.9,".SPX":0.9,"UPRO":0.9,"ESmain":0.9,"IVV":0.9,"OEF":0.9,"SH":0.9,"SDS":0.9,"SPXU":0.9,"OEX":0.9}},"isVote":1,"tweetType":1,"viewCount":1506,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":895270190,"gmtCreate":1628752014110,"gmtModify":1676529842498,"author":{"id":"3579760220696360","authorId":"3579760220696360","name":"Ah Hao","avatar":"https://static.tigerbbs.com/ab98bd75f814e47f112190452ed8a673","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3579760220696360","idStr":"3579760220696360"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/895270190","repostId":"1188642603","repostType":4,"repost":{"id":"1188642603","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628730782,"share":"https://ttm.financial/m/news/1188642603?lang=en_US&edition=fundamental","pubTime":"2021-08-12 09:13","market":"hk","language":"zh","title":"Syrida Medical-B will launch its IPO today, and the admission fee is about HK $24,039.83","url":"https://stock-news.laohu8.com/highlight/detail?id=1188642603","media":"老虎资讯综合","summary":"8月12日，先瑞达医疗-B发布公告，公司拟全球发售6863.3万股股份，其中香港发售股份686.4万股，国际发售股份6176.9万股，另有15%超额配股权；2021年8月12日至8月17日招股，预期定","content":"<p>August 12th,<a href=\"https://laohu8.com/S/06669\">Syntec Medical-B</a>Announced that the company plans to sell 68.633 million shares globally, including 6.864 million shares offered in Hong Kong, 61.769 million shares offered internationally, and a 15% over-allotment option; The IPO will be held from August 12 to August 17, 2021, and the expected pricing date will be August 17; The offer price is HK $22.20-HK $23.80 per offer share, each lot is 1,000 shares, and the admission fee is approximately HK $24,039.83;<a href=\"https://laohu8.com/S/MS\">Morgan Stanley</a>(b)<a href=\"https://laohu8.com/S/601995\">CICC</a>Are the Joint Sponsors; It is expected that the Shares will be listed on the Main Board of the Stock Exchange on 24 August 2021.</p><p><img src=\"https://static.tigerbbs.com/9931b08d27b1f71c11b8c7062a321d29\" tg-width=\"797\" tg-height=\"679\" referrerpolicy=\"no-referrer\"></p><p><b>Subscription ladder:</b></p><p>There are 1,000 shares per lot, and the admission fee is HK $24,039.83.</p><p>The threshold for Group B is 250,000 shares, and the funds required for subscription are approximately HK $6,009,958.15.</p><p><img src=\"https://static.tigerbbs.com/f3b98039f4d7a2c8bd047fdfc65bb21d\" tg-width=\"909\" tg-height=\"642\" referrerpolicy=\"no-referrer\"></p><p>The Group is a leading Chinese<a href=\"https://laohu8.com/S/002173\">Innovative medical care</a>Device companies, with the concept of \"intervention without implantation\", provide a variety of vascular disease treatment options. The Group has developed a number of interventional medical devices with world-leading technologies, especially in the field of drug-coated balloons (DCB) and thrombus aspiration catheters. In 2016, the Group developed and launched China's first peripheral DCB product, approximately four years ahead of the second similar product, and in terms of revenue generated in 2020, the Group's first peripheral DCB product sold approximately 86.9% market share dominates China's peripheral DCB market. The Group's second DCB product was recognized as a \"breakthrough device\" by the FDA in 2019 because it can provide more effective treatment when humans are in irreversibly debilitated, and compared with existing approved or approved products Compared with alternative medical devices, this product has obvious advantages. The product is also considered to demonstrate that it is a breakthrough technology, and the availability of technology is in the best interests of patients. After the product is recognized, it enjoys the right of FDA to speed up the development, evaluation and review process. The product was also approved for marketing by the State Food and Drug Administration in December 2020, becoming the world's first (and as of the Latest Practicable Date, the world's only) treatment under-knee (BTK) DCB product approved by regulatory authorities based on the results of multi-center randomized controlled clinical trials.</p><p>The Group's DCB products adopt the world's leading drug coating technology. According to the results of clinical trials conducted by the Group on these products, the clinical performance of the Group's DCB products is excellent. The Group is also building a comprehensive product pipeline, covering 24 products under development at different stages of development as of the Latest Practicable Date. The Group believes that the Group's first-mover advantage, world-class technology, dominant market share in China and comprehensive product pipeline have established high entry barriers that competitors can't overcome. The Group's mission is to become the world's leading provider of interventional devices for vascular diseases that can provide a complete set of \"interventional without implantation\" solutions. The Group is also expanding the range of indications for the Group's DCB products for the treatment of AVF stenosis, VAO stenosis and erectile dysfunction, facing unique challenges, risks and uncertainties. The Group may not be able to successfully develop and market the Group's core products suitable for the treatment of these diseases.</p><p>The Group has entered into a cornerstone investment agreement with the cornerstone investor, pursuant to which the cornerstone investor has agreed to subscribe for the relevant number of shares that can be purchased for a total amount of US $105 million (or approximately HK $815.63 million) at the Offer Price subject to certain conditions. Assuming an Offer Price of HK $23.00 (i.e. the mid-point of the Offer Price range), the total number of Offer Shares to be subscribed by cornerstone investors is 35.454 million Offer Shares, equivalent to approximately 51.66% of the Offer Shares under the Global Offering and immediately following The total issued share capital of the Group after the completion of the Global Offering is approximately 11.31% (assuming the over-allotment option is not exercised).</p><p>Cornerstone investors include China Universal Fund CPE Investment Wu Limited,<a href=\"https://laohu8.com/S/03908\">CICC</a>The Valliance Fund, Perseverance Asset Management International (Singapore) Pte. Ltd., Daguan International Limited , Athos Asia Event Driven Master Fund, Panjing Harbourview Investment Fund, Dymon Asia Capital (Singapore) Pte. Ltd., Baoyin Asset Management Co., Ltd., PRIMEONE LUCK LIMITED, E Fund, and New Miles Hospital Group Co., Ltd.</p><p><img src=\"https://static.tigerbbs.com/8bb5af7ffecf4e504df277414e8f22d9\" tg-width=\"832\" tg-height=\"729\" referrerpolicy=\"no-referrer\"></p><p>The Group estimates that assuming the Over-allotment Option is not exercised and the Offer Price is HK $23.00 per share (the mid-point of the Offer Price range), the net proceeds from the Global Offering that the Group will receive will be approximately HK $1,473.6 million. The Group currently plans to allocate 32% of these net proceeds to the Group's core products (namely AcoArt TulipTM & LitosTM and AcoArt Orchid & DhaliaTM); 23% will be allocated to the remaining 24 products in the Group's existing product pipeline; 7% will be used to expand production capacity and strengthen manufacturing capacity. The Group plans to lease or purchase a property with an area of about 20,000 square meters to expand its production facilities; 24% will be allocated to provide funds for the expansion of the Group's product portfolio through, among other things, internal research and development, cooperation, mergers and acquisitions, licensing introduction or equity investment; 8% will be used for the group's working capital and general corporate purposes; And 6% will be used to repay January 2021 from<a href=\"https://laohu8.com/S/SIVB\">Silicon Valley Bank</a>Of loans.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Syrida Medical-B will launch its IPO today, and the admission fee is about HK $24,039.83</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSyrida Medical-B will launch its IPO today, and the admission fee is about HK $24,039.83\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-08-12 09:13</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>August 12th,<a href=\"https://laohu8.com/S/06669\">Syntec Medical-B</a>Announced that the company plans to sell 68.633 million shares globally, including 6.864 million shares offered in Hong Kong, 61.769 million shares offered internationally, and a 15% over-allotment option; The IPO will be held from August 12 to August 17, 2021, and the expected pricing date will be August 17; The offer price is HK $22.20-HK $23.80 per offer share, each lot is 1,000 shares, and the admission fee is approximately HK $24,039.83;<a href=\"https://laohu8.com/S/MS\">Morgan Stanley</a>(b)<a href=\"https://laohu8.com/S/601995\">CICC</a>Are the Joint Sponsors; It is expected that the Shares will be listed on the Main Board of the Stock Exchange on 24 August 2021.</p><p><img src=\"https://static.tigerbbs.com/9931b08d27b1f71c11b8c7062a321d29\" tg-width=\"797\" tg-height=\"679\" referrerpolicy=\"no-referrer\"></p><p><b>Subscription ladder:</b></p><p>There are 1,000 shares per lot, and the admission fee is HK $24,039.83.</p><p>The threshold for Group B is 250,000 shares, and the funds required for subscription are approximately HK $6,009,958.15.</p><p><img src=\"https://static.tigerbbs.com/f3b98039f4d7a2c8bd047fdfc65bb21d\" tg-width=\"909\" tg-height=\"642\" referrerpolicy=\"no-referrer\"></p><p>The Group is a leading Chinese<a href=\"https://laohu8.com/S/002173\">Innovative medical care</a>Device companies, with the concept of \"intervention without implantation\", provide a variety of vascular disease treatment options. The Group has developed a number of interventional medical devices with world-leading technologies, especially in the field of drug-coated balloons (DCB) and thrombus aspiration catheters. In 2016, the Group developed and launched China's first peripheral DCB product, approximately four years ahead of the second similar product, and in terms of revenue generated in 2020, the Group's first peripheral DCB product sold approximately 86.9% market share dominates China's peripheral DCB market. The Group's second DCB product was recognized as a \"breakthrough device\" by the FDA in 2019 because it can provide more effective treatment when humans are in irreversibly debilitated, and compared with existing approved or approved products Compared with alternative medical devices, this product has obvious advantages. The product is also considered to demonstrate that it is a breakthrough technology, and the availability of technology is in the best interests of patients. After the product is recognized, it enjoys the right of FDA to speed up the development, evaluation and review process. The product was also approved for marketing by the State Food and Drug Administration in December 2020, becoming the world's first (and as of the Latest Practicable Date, the world's only) treatment under-knee (BTK) DCB product approved by regulatory authorities based on the results of multi-center randomized controlled clinical trials.</p><p>The Group's DCB products adopt the world's leading drug coating technology. According to the results of clinical trials conducted by the Group on these products, the clinical performance of the Group's DCB products is excellent. The Group is also building a comprehensive product pipeline, covering 24 products under development at different stages of development as of the Latest Practicable Date. The Group believes that the Group's first-mover advantage, world-class technology, dominant market share in China and comprehensive product pipeline have established high entry barriers that competitors can't overcome. The Group's mission is to become the world's leading provider of interventional devices for vascular diseases that can provide a complete set of \"interventional without implantation\" solutions. The Group is also expanding the range of indications for the Group's DCB products for the treatment of AVF stenosis, VAO stenosis and erectile dysfunction, facing unique challenges, risks and uncertainties. The Group may not be able to successfully develop and market the Group's core products suitable for the treatment of these diseases.</p><p>The Group has entered into a cornerstone investment agreement with the cornerstone investor, pursuant to which the cornerstone investor has agreed to subscribe for the relevant number of shares that can be purchased for a total amount of US $105 million (or approximately HK $815.63 million) at the Offer Price subject to certain conditions. Assuming an Offer Price of HK $23.00 (i.e. the mid-point of the Offer Price range), the total number of Offer Shares to be subscribed by cornerstone investors is 35.454 million Offer Shares, equivalent to approximately 51.66% of the Offer Shares under the Global Offering and immediately following The total issued share capital of the Group after the completion of the Global Offering is approximately 11.31% (assuming the over-allotment option is not exercised).</p><p>Cornerstone investors include China Universal Fund CPE Investment Wu Limited,<a href=\"https://laohu8.com/S/03908\">CICC</a>The Valliance Fund, Perseverance Asset Management International (Singapore) Pte. Ltd., Daguan International Limited , Athos Asia Event Driven Master Fund, Panjing Harbourview Investment Fund, Dymon Asia Capital (Singapore) Pte. Ltd., Baoyin Asset Management Co., Ltd., PRIMEONE LUCK LIMITED, E Fund, and New Miles Hospital Group Co., Ltd.</p><p><img src=\"https://static.tigerbbs.com/8bb5af7ffecf4e504df277414e8f22d9\" tg-width=\"832\" tg-height=\"729\" referrerpolicy=\"no-referrer\"></p><p>The Group estimates that assuming the Over-allotment Option is not exercised and the Offer Price is HK $23.00 per share (the mid-point of the Offer Price range), the net proceeds from the Global Offering that the Group will receive will be approximately HK $1,473.6 million. The Group currently plans to allocate 32% of these net proceeds to the Group's core products (namely AcoArt TulipTM & LitosTM and AcoArt Orchid & DhaliaTM); 23% will be allocated to the remaining 24 products in the Group's existing product pipeline; 7% will be used to expand production capacity and strengthen manufacturing capacity. The Group plans to lease or purchase a property with an area of about 20,000 square meters to expand its production facilities; 24% will be allocated to provide funds for the expansion of the Group's product portfolio through, among other things, internal research and development, cooperation, mergers and acquisitions, licensing introduction or equity investment; 8% will be used for the group's working capital and general corporate purposes; And 6% will be used to repay January 2021 from<a href=\"https://laohu8.com/S/SIVB\">Silicon Valley Bank</a>Of loans.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/e2bc484766922e67d87fdb952e5532ab","relate_stocks":{"06669":"先瑞达医疗-B"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188642603","content_text":"8月12日，先瑞达医疗-B发布公告，公司拟全球发售6863.3万股股份，其中香港发售股份686.4万股，国际发售股份6176.9万股，另有15%超额配股权；2021年8月12日至8月17日招股，预期定价日为8月17日；发售价每股发售股份22.20港元-23.80港元，每手买卖单位1000股，入场费约24039.83港元；摩根士丹利及中金公司为联席保荐人；预期股份将于2021年8月24日于联交所主板挂牌上市。\n\n申购阶梯：\n每手1000股，入场费24039.83港元。\n乙组门槛为25万股，申购所需资金约6009958.15港元。\n\n集团是一家领先的中国创新医疗器械企业，以“介入无植入”为理念，提供多种血管疾病治疗方案。集团研发了多款具有世界领先技术(尤其在药物涂层球囊(DCB)领域以及血栓抽吸导管领域)的介入医疗器械。2016年，集团开发并推出了中国首款外周DCB产品，比第二款同类产品领先约四年的时间，以及以2020年产生的收益计，集团的首款外周DCB产品以约86.9%的市场份额在中国外周DCB市场中占据主导地位。集团的第二款DCB产品于2019年被FDA认定为“突破性器械”，原因为该产品能够在人类处于不可逆转衰弱状态的情况下提供更有效治疗，且与现有获认可或经批准的替代医疗器械相比，该产品具有明显优势。该产品被认为亦表明其乃一项突破性技术，技术的可利用性符合患者的最佳利益。该产品被认定后享有FDA加快开发、评估及评审过程的权利。该产品亦于2020年12月获得国家药监局批准上市，成为全球首款(截至最后实际可行日期，也是全球唯一一款)基于多中心随机对照临床试验结果而获监管部门批准上市的治疗膝下(BTK)DCB产品。\n集团的DCB产品采用了全球领先的药物涂层技术，根据集团就该等产品所进行临床试验的结果，集团的DCB产品的临床表现出色。集团亦正在打造一个全面的产品管线，截至最后实际可行日期，涵盖24款处于不同开发阶段的在研产品。集团认为，集团的先发优势、世界级的技术、在中国的主导性市场份额及全面的产品管线为集团建立了竞争对手难以逾越的高准入壁垒。集团的使命是成为全球领先的、可提供全套“介入无植入”解决方案的血管疾病介入器械提供商。集团亦正在扩阔集团治疗AVF狭窄、VAO狭窄及勃起功能障碍的DCB产品的适应症范围，就此面对独特的挑战、风险及不确定因素。集团可能无法成功开发及营销集团适用于治疗该等疾病的核心产品。\n集团已与基石投资者订立基石投资协议，据此，基石投资者已同意在若干条件的规限下按发售价认购总金额1.05亿美元(或约8.1563亿港元)可购买的有关数目的发售股份。假设发售价为23.00港元(即发售价范围中位数)，基石投资者将予认购的发售股份总数为3545.4万股发售股份，相当于全球发售项下的发售股份约51.66%及紧随全球发售完成后集团的已发行股本总额约11.31%(假设超额配股权未获行使)。\n基石投资者包括汇添富基金、CPE Investment Wu Limited、中金公司、The Valliance Fund、Perseverance Asset Management International (Singapore) Pte. Ltd.、达观国际有限公司、Athos Asia Event Driven Master Fund、Panjing Harbourview Investment Fund、Dymon Asia Capital (Singapore) Pte. Ltd.、保银资产管理有限公司、PRIMEONE LUCK LIMITED、易方达基金、及新里程医院集团有限公司。\n\n集团估计，假设超额配股权未获行使及发售价为每股23.00港元(即发售价范围中位数)，集团将收到的全球发售所得款项净额约为14.736亿港元。集团目前计划将该等所得款项净额32%分配予集团的核心产品(即AcoArt TulipTM& LitosTM及AcoArt Orchid& DhaliaTM)；23%将被分配予集团现有产品管线中余下的24款产品；7%将用于扩大生产能力及强化制造能力。集团计划租赁或购买一处面积约2万平方米的物业以扩大生产设施；24%将获分配用于为通过(其中包括)内部研发、合作、合并及收购、授权引进或股权投资等方式扩大集团的产品组合提供资金；8%将用于集团的营运资金及一般企业用途；及6%将用于偿还2021年1月来自硅谷银行的贷款。","news_type":1,"symbols_score_info":{"06669":0.9}},"isVote":1,"tweetType":1,"viewCount":1852,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9006233508,"gmtCreate":1641749420496,"gmtModify":1676533644495,"author":{"id":"3579760220696360","authorId":"3579760220696360","name":"Ah Hao","avatar":"https://static.tigerbbs.com/ab98bd75f814e47f112190452ed8a673","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3579760220696360","idStr":"3579760220696360"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006233508","repostId":"2201249471","repostType":2,"repost":{"id":"2201249471","kind":"highlight","pubTimestamp":1641691426,"share":"https://ttm.financial/m/news/2201249471?lang=en_US&edition=fundamental","pubTime":"2022-01-09 09:23","market":"us","language":"en","title":"My 3 Favorite Stocks Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2201249471","media":"Motley Fool","summary":"These glaring deals from the small and mid-cap arena could be substantial long-term winners.","content":"<div>\n<p>Unless a portfolio is constructed entirely of mega-cap stocks, it's probably seeing more red than green days lately. The market can seem like a popularity contest, and small and mid-cap growth stocks ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/08/my-3-favorite-stocks-right-now/\">Source Link</a>\n\n</div>\n","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>My 3 Favorite Stocks Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMy 3 Favorite Stocks Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-09 09:23 GMT+8 <a href=https://www.fool.com/investing/2022/01/08/my-3-favorite-stocks-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Unless a portfolio is constructed entirely of mega-cap stocks, it's probably seeing more red than green days lately. The market can seem like a popularity contest, and small and mid-cap growth stocks ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/08/my-3-favorite-stocks-right-now/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4554":"元宇宙及AR概念","AFRM":"Affirm Holdings, Inc.","SE":"Sea Ltd","BK4551":"寇图资本持仓","BK4566":"资本集团","BK4528":"SaaS概念","BK4097":"系统软件","CRWD":"CrowdStrike Holdings, Inc.","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","BK4503":"景林资产持仓","BK4560":"网络安全概念","BK4532":"文艺复兴科技持仓","BK4106":"数据处理与外包服务","BK4085":"互动家庭娱乐"},"source_url":"https://www.fool.com/investing/2022/01/08/my-3-favorite-stocks-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201249471","content_text":"Unless a portfolio is constructed entirely of mega-cap stocks, it's probably seeing more red than green days lately. The market can seem like a popularity contest, and small and mid-cap growth stocks are not cool right now.But it would help if investors looked at the positives in all of this selling pressure. With so many stocks selling off, it's a great time to buy stocks at great prices. The market has hammered these three stocks recently, but they have a long-term upside that could make them huge winners down the road.1. Affirm HoldingsBuy now, pay later (BNPL) took 2021 by storm, growing roughly fourfold to $100 billion this past year. Experts think it could expand to 15 times its current volume by 2025. The simple structure of fixed installments that often carry zero interest is rapidly gaining popularity over traditional consumer credit cards.Image source: Getty Images.Affirm (NASDAQ:AFRM) is one of the leading BNPL companies. It works with its retail partners to offer installment payment plans on products. Users can shop right from the Affirm app and use Affirm's payment tools when checking out. Retailers have an incentive to use BNPL because it increases order size and customer loyalty. Shoppers can fit more into their carts, and they like the simple financing. In other words, it has become a sales tool for retailers.Affirm has secured numerous partnerships with leading e-commerce merchants, including Amazon, Walmart, Shopify, and Target. In its first quarter of 2022 (period ending Sept. 30, 2021), the company reported that its merchant partnerships had increased 1,468% year over year to 102,200. Affirm hasn't even commented on its guidance since announcing the Amazon partnership, so it seems reasonable that its 84% year-over-year merchandise volume growth in 2022 Q1 could continue from here.Despite this good news, the stock has been caught up in a broader market tech sell-off and has fallen more than 50% from its highs. At $80 per share, the stock almost trades as low as before Affirm announced the Amazon partnership.Affirm isn't profitable, but it's spending heavily on building new products and services; it has ambitions of becoming a broader financial services company, bringing a finance super-app and debit card to market over the coming quarters. As these products launch and revenue grows, investors should look for the business to begin heading toward a positive operating income.2. Crowdstrike HoldingsThe world is becoming increasingly digital at a rapid pace. Yet, consumers' and businesses' tools to protect themselves from digital threats are largely still behind the times. Someone could do a simple internet search and find countless instances of breached, hacked, or compromised companies.CrowdStrike (NASDAQ:CRWD) is a cloud-based leader in endpoint security, in which a network protects user devices like computers and mobile devices from digital threats. In the old days, people would download antivirus software, receive occasional updates from the security company which ultimately would tell the antivirus program what threats looked like.CrowdStrike's Falcon platform delivers various protections through the cloud, giving the software real-time information and updates. Devices connected on Falcon are linked, similar to a massive network. If an attack happens on one device, the system learns and instantly shares this information with the other devices throughout the network. As more devices are connected, it creates a network effect, and the Falcon platform learns more, faster.The stock has had a great run since COVID-19 started but has since pulled back roughly 40% from its highs. CrowdStrike grew subscription revenue 67% year over year in its most recent quarter, the third quarter of 2022 (Oct. 31, 2021), to $357 million. The company is reporting net losses but is growing its free cash flow; it was $123.5 million in 2022 Q3, a 62% year-over-year increase. Free cash flow is a positive step toward posting a profit, so investors should look for cash flow to keep growing, and net losses to shrink over the coming quarters.3. Sea LimitedThe population in Southeast Asia is friendly toward technology; the region boasts a population of roughly 670 million, and half are under age 30. They also tend to spend eight hours on the internet each day, more than the global average. In other words, they are a great target market for digital businesses.Sea Limited (NYSE:SE) is an internet company with various digital business segments, including e-commerce, mobile gaming, and financial services. Garena, its gaming business, is driven by FreeFire, one of the most popular mobile games in the world. It's also the most profitable part of the company, responsible for all of Sea's adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA).The company uses these profits to expand other parts of its business heavily. For example, Sea has taken its e-commerce business, Shopee, to other regions in the world, including Latin America, Europe, and India. The company is aggressively pumping its cash back into the business to pay for the employees, buildings, and resources needed for these new markets, so the overall business is losing money right now. However, I expect that the spending eventually levels off, and revenue growth will outpace the money Sea spends, pushing the company toward profits. Investors will want to pay attention to whether losses grow or shrink in future quarters.Sea's total revenue grew 122% year over year in its most recent quarter, 2021 Q3, and there is reason to believe that rapid growth can continue for years to come. E-commerce, gaming, and fintech are all massive addressable markets, and Sea's ambition to attack them at a global scale gives the business a virtually endless runway for growth. The stock is 50% off its highs, so investors with the patience to hold for the long term could be scooping up shares at a nice discount.","news_type":1,"symbols_score_info":{"AFRM":1,"SE":1,"CRWD":1}},"isVote":1,"tweetType":1,"viewCount":2181,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":895270190,"gmtCreate":1628752014110,"gmtModify":1676529842498,"author":{"id":"3579760220696360","authorId":"3579760220696360","name":"Ah Hao","avatar":"https://static.tigerbbs.com/ab98bd75f814e47f112190452ed8a673","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3579760220696360","idStr":"3579760220696360"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/895270190","repostId":"1188642603","repostType":4,"repost":{"id":"1188642603","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628730782,"share":"https://ttm.financial/m/news/1188642603?lang=en_US&edition=fundamental","pubTime":"2021-08-12 09:13","market":"hk","language":"zh","title":"Syrida Medical-B will launch its IPO today, and the admission fee is about HK $24,039.83","url":"https://stock-news.laohu8.com/highlight/detail?id=1188642603","media":"老虎资讯综合","summary":"8月12日，先瑞达医疗-B发布公告，公司拟全球发售6863.3万股股份，其中香港发售股份686.4万股，国际发售股份6176.9万股，另有15%超额配股权；2021年8月12日至8月17日招股，预期定","content":"<p>August 12th,<a href=\"https://laohu8.com/S/06669\">Syntec Medical-B</a>Announced that the company plans to sell 68.633 million shares globally, including 6.864 million shares offered in Hong Kong, 61.769 million shares offered internationally, and a 15% over-allotment option; The IPO will be held from August 12 to August 17, 2021, and the expected pricing date will be August 17; The offer price is HK $22.20-HK $23.80 per offer share, each lot is 1,000 shares, and the admission fee is approximately HK $24,039.83;<a href=\"https://laohu8.com/S/MS\">Morgan Stanley</a>(b)<a href=\"https://laohu8.com/S/601995\">CICC</a>Are the Joint Sponsors; It is expected that the Shares will be listed on the Main Board of the Stock Exchange on 24 August 2021.</p><p><img src=\"https://static.tigerbbs.com/9931b08d27b1f71c11b8c7062a321d29\" tg-width=\"797\" tg-height=\"679\" referrerpolicy=\"no-referrer\"></p><p><b>Subscription ladder:</b></p><p>There are 1,000 shares per lot, and the admission fee is HK $24,039.83.</p><p>The threshold for Group B is 250,000 shares, and the funds required for subscription are approximately HK $6,009,958.15.</p><p><img src=\"https://static.tigerbbs.com/f3b98039f4d7a2c8bd047fdfc65bb21d\" tg-width=\"909\" tg-height=\"642\" referrerpolicy=\"no-referrer\"></p><p>The Group is a leading Chinese<a href=\"https://laohu8.com/S/002173\">Innovative medical care</a>Device companies, with the concept of \"intervention without implantation\", provide a variety of vascular disease treatment options. The Group has developed a number of interventional medical devices with world-leading technologies, especially in the field of drug-coated balloons (DCB) and thrombus aspiration catheters. In 2016, the Group developed and launched China's first peripheral DCB product, approximately four years ahead of the second similar product, and in terms of revenue generated in 2020, the Group's first peripheral DCB product sold approximately 86.9% market share dominates China's peripheral DCB market. The Group's second DCB product was recognized as a \"breakthrough device\" by the FDA in 2019 because it can provide more effective treatment when humans are in irreversibly debilitated, and compared with existing approved or approved products Compared with alternative medical devices, this product has obvious advantages. The product is also considered to demonstrate that it is a breakthrough technology, and the availability of technology is in the best interests of patients. After the product is recognized, it enjoys the right of FDA to speed up the development, evaluation and review process. The product was also approved for marketing by the State Food and Drug Administration in December 2020, becoming the world's first (and as of the Latest Practicable Date, the world's only) treatment under-knee (BTK) DCB product approved by regulatory authorities based on the results of multi-center randomized controlled clinical trials.</p><p>The Group's DCB products adopt the world's leading drug coating technology. According to the results of clinical trials conducted by the Group on these products, the clinical performance of the Group's DCB products is excellent. The Group is also building a comprehensive product pipeline, covering 24 products under development at different stages of development as of the Latest Practicable Date. The Group believes that the Group's first-mover advantage, world-class technology, dominant market share in China and comprehensive product pipeline have established high entry barriers that competitors can't overcome. The Group's mission is to become the world's leading provider of interventional devices for vascular diseases that can provide a complete set of \"interventional without implantation\" solutions. The Group is also expanding the range of indications for the Group's DCB products for the treatment of AVF stenosis, VAO stenosis and erectile dysfunction, facing unique challenges, risks and uncertainties. The Group may not be able to successfully develop and market the Group's core products suitable for the treatment of these diseases.</p><p>The Group has entered into a cornerstone investment agreement with the cornerstone investor, pursuant to which the cornerstone investor has agreed to subscribe for the relevant number of shares that can be purchased for a total amount of US $105 million (or approximately HK $815.63 million) at the Offer Price subject to certain conditions. Assuming an Offer Price of HK $23.00 (i.e. the mid-point of the Offer Price range), the total number of Offer Shares to be subscribed by cornerstone investors is 35.454 million Offer Shares, equivalent to approximately 51.66% of the Offer Shares under the Global Offering and immediately following The total issued share capital of the Group after the completion of the Global Offering is approximately 11.31% (assuming the over-allotment option is not exercised).</p><p>Cornerstone investors include China Universal Fund CPE Investment Wu Limited,<a href=\"https://laohu8.com/S/03908\">CICC</a>The Valliance Fund, Perseverance Asset Management International (Singapore) Pte. Ltd., Daguan International Limited , Athos Asia Event Driven Master Fund, Panjing Harbourview Investment Fund, Dymon Asia Capital (Singapore) Pte. Ltd., Baoyin Asset Management Co., Ltd., PRIMEONE LUCK LIMITED, E Fund, and New Miles Hospital Group Co., Ltd.</p><p><img src=\"https://static.tigerbbs.com/8bb5af7ffecf4e504df277414e8f22d9\" tg-width=\"832\" tg-height=\"729\" referrerpolicy=\"no-referrer\"></p><p>The Group estimates that assuming the Over-allotment Option is not exercised and the Offer Price is HK $23.00 per share (the mid-point of the Offer Price range), the net proceeds from the Global Offering that the Group will receive will be approximately HK $1,473.6 million. The Group currently plans to allocate 32% of these net proceeds to the Group's core products (namely AcoArt TulipTM & LitosTM and AcoArt Orchid & DhaliaTM); 23% will be allocated to the remaining 24 products in the Group's existing product pipeline; 7% will be used to expand production capacity and strengthen manufacturing capacity. The Group plans to lease or purchase a property with an area of about 20,000 square meters to expand its production facilities; 24% will be allocated to provide funds for the expansion of the Group's product portfolio through, among other things, internal research and development, cooperation, mergers and acquisitions, licensing introduction or equity investment; 8% will be used for the group's working capital and general corporate purposes; And 6% will be used to repay January 2021 from<a href=\"https://laohu8.com/S/SIVB\">Silicon Valley Bank</a>Of loans.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Syrida Medical-B will launch its IPO today, and the admission fee is about HK $24,039.83</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSyrida Medical-B will launch its IPO today, and the admission fee is about HK $24,039.83\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-08-12 09:13</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>August 12th,<a href=\"https://laohu8.com/S/06669\">Syntec Medical-B</a>Announced that the company plans to sell 68.633 million shares globally, including 6.864 million shares offered in Hong Kong, 61.769 million shares offered internationally, and a 15% over-allotment option; The IPO will be held from August 12 to August 17, 2021, and the expected pricing date will be August 17; The offer price is HK $22.20-HK $23.80 per offer share, each lot is 1,000 shares, and the admission fee is approximately HK $24,039.83;<a href=\"https://laohu8.com/S/MS\">Morgan Stanley</a>(b)<a href=\"https://laohu8.com/S/601995\">CICC</a>Are the Joint Sponsors; It is expected that the Shares will be listed on the Main Board of the Stock Exchange on 24 August 2021.</p><p><img src=\"https://static.tigerbbs.com/9931b08d27b1f71c11b8c7062a321d29\" tg-width=\"797\" tg-height=\"679\" referrerpolicy=\"no-referrer\"></p><p><b>Subscription ladder:</b></p><p>There are 1,000 shares per lot, and the admission fee is HK $24,039.83.</p><p>The threshold for Group B is 250,000 shares, and the funds required for subscription are approximately HK $6,009,958.15.</p><p><img src=\"https://static.tigerbbs.com/f3b98039f4d7a2c8bd047fdfc65bb21d\" tg-width=\"909\" tg-height=\"642\" referrerpolicy=\"no-referrer\"></p><p>The Group is a leading Chinese<a href=\"https://laohu8.com/S/002173\">Innovative medical care</a>Device companies, with the concept of \"intervention without implantation\", provide a variety of vascular disease treatment options. The Group has developed a number of interventional medical devices with world-leading technologies, especially in the field of drug-coated balloons (DCB) and thrombus aspiration catheters. In 2016, the Group developed and launched China's first peripheral DCB product, approximately four years ahead of the second similar product, and in terms of revenue generated in 2020, the Group's first peripheral DCB product sold approximately 86.9% market share dominates China's peripheral DCB market. The Group's second DCB product was recognized as a \"breakthrough device\" by the FDA in 2019 because it can provide more effective treatment when humans are in irreversibly debilitated, and compared with existing approved or approved products Compared with alternative medical devices, this product has obvious advantages. The product is also considered to demonstrate that it is a breakthrough technology, and the availability of technology is in the best interests of patients. After the product is recognized, it enjoys the right of FDA to speed up the development, evaluation and review process. The product was also approved for marketing by the State Food and Drug Administration in December 2020, becoming the world's first (and as of the Latest Practicable Date, the world's only) treatment under-knee (BTK) DCB product approved by regulatory authorities based on the results of multi-center randomized controlled clinical trials.</p><p>The Group's DCB products adopt the world's leading drug coating technology. According to the results of clinical trials conducted by the Group on these products, the clinical performance of the Group's DCB products is excellent. The Group is also building a comprehensive product pipeline, covering 24 products under development at different stages of development as of the Latest Practicable Date. The Group believes that the Group's first-mover advantage, world-class technology, dominant market share in China and comprehensive product pipeline have established high entry barriers that competitors can't overcome. The Group's mission is to become the world's leading provider of interventional devices for vascular diseases that can provide a complete set of \"interventional without implantation\" solutions. The Group is also expanding the range of indications for the Group's DCB products for the treatment of AVF stenosis, VAO stenosis and erectile dysfunction, facing unique challenges, risks and uncertainties. The Group may not be able to successfully develop and market the Group's core products suitable for the treatment of these diseases.</p><p>The Group has entered into a cornerstone investment agreement with the cornerstone investor, pursuant to which the cornerstone investor has agreed to subscribe for the relevant number of shares that can be purchased for a total amount of US $105 million (or approximately HK $815.63 million) at the Offer Price subject to certain conditions. Assuming an Offer Price of HK $23.00 (i.e. the mid-point of the Offer Price range), the total number of Offer Shares to be subscribed by cornerstone investors is 35.454 million Offer Shares, equivalent to approximately 51.66% of the Offer Shares under the Global Offering and immediately following The total issued share capital of the Group after the completion of the Global Offering is approximately 11.31% (assuming the over-allotment option is not exercised).</p><p>Cornerstone investors include China Universal Fund CPE Investment Wu Limited,<a href=\"https://laohu8.com/S/03908\">CICC</a>The Valliance Fund, Perseverance Asset Management International (Singapore) Pte. Ltd., Daguan International Limited , Athos Asia Event Driven Master Fund, Panjing Harbourview Investment Fund, Dymon Asia Capital (Singapore) Pte. Ltd., Baoyin Asset Management Co., Ltd., PRIMEONE LUCK LIMITED, E Fund, and New Miles Hospital Group Co., Ltd.</p><p><img src=\"https://static.tigerbbs.com/8bb5af7ffecf4e504df277414e8f22d9\" tg-width=\"832\" tg-height=\"729\" referrerpolicy=\"no-referrer\"></p><p>The Group estimates that assuming the Over-allotment Option is not exercised and the Offer Price is HK $23.00 per share (the mid-point of the Offer Price range), the net proceeds from the Global Offering that the Group will receive will be approximately HK $1,473.6 million. The Group currently plans to allocate 32% of these net proceeds to the Group's core products (namely AcoArt TulipTM & LitosTM and AcoArt Orchid & DhaliaTM); 23% will be allocated to the remaining 24 products in the Group's existing product pipeline; 7% will be used to expand production capacity and strengthen manufacturing capacity. The Group plans to lease or purchase a property with an area of about 20,000 square meters to expand its production facilities; 24% will be allocated to provide funds for the expansion of the Group's product portfolio through, among other things, internal research and development, cooperation, mergers and acquisitions, licensing introduction or equity investment; 8% will be used for the group's working capital and general corporate purposes; And 6% will be used to repay January 2021 from<a href=\"https://laohu8.com/S/SIVB\">Silicon Valley Bank</a>Of loans.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/e2bc484766922e67d87fdb952e5532ab","relate_stocks":{"06669":"先瑞达医疗-B"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188642603","content_text":"8月12日，先瑞达医疗-B发布公告，公司拟全球发售6863.3万股股份，其中香港发售股份686.4万股，国际发售股份6176.9万股，另有15%超额配股权；2021年8月12日至8月17日招股，预期定价日为8月17日；发售价每股发售股份22.20港元-23.80港元，每手买卖单位1000股，入场费约24039.83港元；摩根士丹利及中金公司为联席保荐人；预期股份将于2021年8月24日于联交所主板挂牌上市。\n\n申购阶梯：\n每手1000股，入场费24039.83港元。\n乙组门槛为25万股，申购所需资金约6009958.15港元。\n\n集团是一家领先的中国创新医疗器械企业，以“介入无植入”为理念，提供多种血管疾病治疗方案。集团研发了多款具有世界领先技术(尤其在药物涂层球囊(DCB)领域以及血栓抽吸导管领域)的介入医疗器械。2016年，集团开发并推出了中国首款外周DCB产品，比第二款同类产品领先约四年的时间，以及以2020年产生的收益计，集团的首款外周DCB产品以约86.9%的市场份额在中国外周DCB市场中占据主导地位。集团的第二款DCB产品于2019年被FDA认定为“突破性器械”，原因为该产品能够在人类处于不可逆转衰弱状态的情况下提供更有效治疗，且与现有获认可或经批准的替代医疗器械相比，该产品具有明显优势。该产品被认为亦表明其乃一项突破性技术，技术的可利用性符合患者的最佳利益。该产品被认定后享有FDA加快开发、评估及评审过程的权利。该产品亦于2020年12月获得国家药监局批准上市，成为全球首款(截至最后实际可行日期，也是全球唯一一款)基于多中心随机对照临床试验结果而获监管部门批准上市的治疗膝下(BTK)DCB产品。\n集团的DCB产品采用了全球领先的药物涂层技术，根据集团就该等产品所进行临床试验的结果，集团的DCB产品的临床表现出色。集团亦正在打造一个全面的产品管线，截至最后实际可行日期，涵盖24款处于不同开发阶段的在研产品。集团认为，集团的先发优势、世界级的技术、在中国的主导性市场份额及全面的产品管线为集团建立了竞争对手难以逾越的高准入壁垒。集团的使命是成为全球领先的、可提供全套“介入无植入”解决方案的血管疾病介入器械提供商。集团亦正在扩阔集团治疗AVF狭窄、VAO狭窄及勃起功能障碍的DCB产品的适应症范围，就此面对独特的挑战、风险及不确定因素。集团可能无法成功开发及营销集团适用于治疗该等疾病的核心产品。\n集团已与基石投资者订立基石投资协议，据此，基石投资者已同意在若干条件的规限下按发售价认购总金额1.05亿美元(或约8.1563亿港元)可购买的有关数目的发售股份。假设发售价为23.00港元(即发售价范围中位数)，基石投资者将予认购的发售股份总数为3545.4万股发售股份，相当于全球发售项下的发售股份约51.66%及紧随全球发售完成后集团的已发行股本总额约11.31%(假设超额配股权未获行使)。\n基石投资者包括汇添富基金、CPE Investment Wu Limited、中金公司、The Valliance Fund、Perseverance Asset Management International (Singapore) Pte. Ltd.、达观国际有限公司、Athos Asia Event Driven Master Fund、Panjing Harbourview Investment Fund、Dymon Asia Capital (Singapore) Pte. Ltd.、保银资产管理有限公司、PRIMEONE LUCK LIMITED、易方达基金、及新里程医院集团有限公司。\n\n集团估计，假设超额配股权未获行使及发售价为每股23.00港元(即发售价范围中位数)，集团将收到的全球发售所得款项净额约为14.736亿港元。集团目前计划将该等所得款项净额32%分配予集团的核心产品(即AcoArt TulipTM& LitosTM及AcoArt Orchid& DhaliaTM)；23%将被分配予集团现有产品管线中余下的24款产品；7%将用于扩大生产能力及强化制造能力。集团计划租赁或购买一处面积约2万平方米的物业以扩大生产设施；24%将获分配用于为通过(其中包括)内部研发、合作、合并及收购、授权引进或股权投资等方式扩大集团的产品组合提供资金；8%将用于集团的营运资金及一般企业用途；及6%将用于偿还2021年1月来自硅谷银行的贷款。","news_type":1,"symbols_score_info":{"06669":0.9}},"isVote":1,"tweetType":1,"viewCount":1852,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9966718672,"gmtCreate":1669643436997,"gmtModify":1676538217670,"author":{"id":"3579760220696360","authorId":"3579760220696360","name":"Ah Hao","avatar":"https://static.tigerbbs.com/ab98bd75f814e47f112190452ed8a673","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3579760220696360","idStr":"3579760220696360"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/SE\">$Sea Ltd(SE)$ </a><v-v data-views=\"1\"></v-v>","listText":"<a href=\"https://ttm.financial/S/SE\">$Sea Ltd(SE)$ </a><v-v data-views=\"1\"></v-v>","text":"$Sea Ltd(SE)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9966718672","isVote":1,"tweetType":1,"viewCount":1833,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9920959334,"gmtCreate":1670423630628,"gmtModify":1676538364825,"author":{"id":"3579760220696360","authorId":"3579760220696360","name":"Ah Hao","avatar":"https://static.tigerbbs.com/ab98bd75f814e47f112190452ed8a673","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3579760220696360","idStr":"3579760220696360"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/OPT/TLT 20221216 106.0 CALL\">$TLT 20221216 106.0 CALL$ </a><a href=\"https://ttm.financial/OPT/TLT 20221216 106.0 CALL\">$TLT 20221216 106.0 CALL$ </a> ","listText":"<a href=\"https://ttm.financial/OPT/TLT 20221216 106.0 CALL\">$TLT 20221216 106.0 CALL$ </a><a href=\"https://ttm.financial/OPT/TLT 20221216 106.0 CALL\">$TLT 20221216 106.0 CALL$ </a> ","text":"$TLT 20221216 106.0 CALL$ $TLT 20221216 106.0 CALL$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9920959334","isVote":1,"tweetType":1,"viewCount":1375,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":863015628,"gmtCreate":1632331437664,"gmtModify":1676530755591,"author":{"id":"3579760220696360","authorId":"3579760220696360","name":"Ah Hao","avatar":"https://static.tigerbbs.com/ab98bd75f814e47f112190452ed8a673","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3579760220696360","idStr":"3579760220696360"},"themes":[],"htmlText":"Hi Hi","listText":"Hi Hi","text":"Hi Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/863015628","repostId":"2169665276","repostType":2,"repost":{"id":"2169665276","kind":"news","pubTimestamp":1632327780,"share":"https://ttm.financial/m/news/2169665276?lang=en_US&edition=fundamental","pubTime":"2021-09-23 00:23","market":"us","language":"zh","title":"Survey: Investors think it's time to take a conservative strategy in the stock market","url":"https://stock-news.laohu8.com/highlight/detail?id=2169665276","media":"新浪美股","summary":"据媒体最新调查，华尔街投资者们认为，随着本月担忧继情绪续加剧，是时候将一些风险排除在外了。 媒体本周对大约400名首席投资官、股票策略师、投资组合经理和媒体撰稿人进行了调查。 尽管投资者目前对市场持更为谨慎的看法，但他们仍认为未来12个月股市可能会走高。约一半的受访者表示，标普500指数在未来12个月内将上涨5%以上。","content":"<p>According to the latest media survey, Wall Street investors believe that as concerns continue to intensify this month, it is time to exclude some risks.</p><p>The media surveyed roughly 400 chief investment officers, equity strategists, portfolio managers and media writers this week. When asked what market risk they are willing to accept for themselves and their clients, more than three-quarters of respondents said it's time to be very conservative in the stock market.<img src=\"https://static.tigerbbs.com/65778cdcafa625d17574b193f4c4294b\" tg-width=\"550\" tg-height=\"195\" referrerpolicy=\"no-referrer\"></p><p>While investors are currently taking a more cautious view of the market, they still think stocks are likely to move higher over the next 12 months. About half of respondents said the S&P 500 would rise more than 5% over the next 12 months. Forty-four percent said it would be essentially flat and five percent said they expect a decline next year.</p><p><img src=\"https://static.tigerbbs.com/0d55b716f44344dafd3c388b94d84c5a\" tg-width=\"550\" tg-height=\"244\" referrerpolicy=\"no-referrer\">Following this week's pullback, the S&P 500 is down about 4.2% from its all-time high set in early September. Many market participants believe that the market is experiencing seasonal weakness.</p><p>\"Market sentiment appears to have shifted in favor of the bears over the past few weeks,\" said Brian Price, head of investment management at Commonwealth Financial Network. \"After a relatively quiet summer, market participants appear to be looking to dampen this year's rally.\"</p><p>Some prominent strategists stick to bullish. Fundstrat co-founder Tom Lee sees Monday's stock market plunge as a buying opportunity for investors.<a href=\"https://laohu8.com/S/JPM\">JPMorgan Chase</a>Strategist Marko Kolanovic also called the sell-off excessive.</p><p>However, one of Wall Street's biggest shorts-<a href=\"https://laohu8.com/S/MS\">Morgan Stanley</a>Mike Wilson of the S&P 500 sees a 20% pullback as some economic indicators begin to deteriorate, which is a \"destructive\" scenario.</p><p>The findings show that the best strategy right now for yield-focused investors is private credit. Only 2% of respondents believe that U.S. Treasury Bond can provide attractive benefits.</p><p>Government bonds are rapidly becoming one of the most disgusting asset classes, as their safe-haven appeal weakens during the economic recovery. Bill Gross, the \"old debt king\", recently called the U.S. Treasury Bond rubbish, saying that the yield of 10-year Treasury Bond in the next 12 months will be around 2%, which is equivalent to a price loss of 4%-5% and a negative return of 2.5%-3%.</p>","source":"sina","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Survey: Investors think it's time to take a conservative strategy in the stock market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSurvey: Investors think it's time to take a conservative strategy in the stock market\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">新浪美股</strong><span class=\"h-time small\">2021-09-23 00:23</span>\n</p>\n</h4>\n</header>\n<article>\n<p>According to the latest media survey, Wall Street investors believe that as concerns continue to intensify this month, it is time to exclude some risks.</p><p>The media surveyed roughly 400 chief investment officers, equity strategists, portfolio managers and media writers this week. When asked what market risk they are willing to accept for themselves and their clients, more than three-quarters of respondents said it's time to be very conservative in the stock market.<img src=\"https://static.tigerbbs.com/65778cdcafa625d17574b193f4c4294b\" tg-width=\"550\" tg-height=\"195\" referrerpolicy=\"no-referrer\"></p><p>While investors are currently taking a more cautious view of the market, they still think stocks are likely to move higher over the next 12 months. About half of respondents said the S&P 500 would rise more than 5% over the next 12 months. Forty-four percent said it would be essentially flat and five percent said they expect a decline next year.</p><p><img src=\"https://static.tigerbbs.com/0d55b716f44344dafd3c388b94d84c5a\" tg-width=\"550\" tg-height=\"244\" referrerpolicy=\"no-referrer\">Following this week's pullback, the S&P 500 is down about 4.2% from its all-time high set in early September. Many market participants believe that the market is experiencing seasonal weakness.</p><p>\"Market sentiment appears to have shifted in favor of the bears over the past few weeks,\" said Brian Price, head of investment management at Commonwealth Financial Network. \"After a relatively quiet summer, market participants appear to be looking to dampen this year's rally.\"</p><p>Some prominent strategists stick to bullish. Fundstrat co-founder Tom Lee sees Monday's stock market plunge as a buying opportunity for investors.<a href=\"https://laohu8.com/S/JPM\">JPMorgan Chase</a>Strategist Marko Kolanovic also called the sell-off excessive.</p><p>However, one of Wall Street's biggest shorts-<a href=\"https://laohu8.com/S/MS\">Morgan Stanley</a>Mike Wilson of the S&P 500 sees a 20% pullback as some economic indicators begin to deteriorate, which is a \"destructive\" scenario.</p><p>The findings show that the best strategy right now for yield-focused investors is private credit. Only 2% of respondents believe that U.S. Treasury Bond can provide attractive benefits.</p><p>Government bonds are rapidly becoming one of the most disgusting asset classes, as their safe-haven appeal weakens during the economic recovery. Bill Gross, the \"old debt king\", recently called the U.S. Treasury Bond rubbish, saying that the yield of 10-year Treasury Bond in the next 12 months will be around 2%, which is equivalent to a price loss of 4%-5% and a negative return of 2.5%-3%.</p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://finance.sina.com.cn/stock/usstock/c/2021-09-23/doc-iktzscyx5742473.shtml\">新浪美股</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/ee61dd9fe3e53070a1d0efed49b773f5","relate_stocks":{"161125":"标普500","513500":"标普500ETF",".SPX":"S&P 500 Index","UPRO":"三倍做多标普500ETF-ProShares","SH":"做空标普500-Proshares","SDS":"两倍做空标普500 ETF-ProShares","OEX":"标普100","IVV":"标普500ETF-iShares","SPXU":"三倍做空标普500ETF-ProShares","OEF":"标普100指数ETF-iShares","SPY":"标普500ETF","SSO":"2倍做多标普500ETF-ProShares"},"source_url":"https://finance.sina.com.cn/stock/usstock/c/2021-09-23/doc-iktzscyx5742473.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","article_id":"2169665276","content_text":"据媒体最新调查，华尔街投资者们认为，随着本月担忧继情绪续加剧，是时候将一些风险排除在外了。\n媒体本周对大约400名首席投资官、股票策略师、投资组合经理和媒体撰稿人进行了调查。当被问及他们愿意为自己和客户接受什么样的市场风险时，超过四分之三的受访者表示，现在是在股市中非常保守的时候了。\n尽管投资者目前对市场持更为谨慎的看法，但他们仍认为未来12个月股市可能会走高。约一半的受访者表示，标普500指数在未来12个月内将上涨5%以上。44%的人表示将基本持平，5%的人表示预计明年会下跌。\n在本周回调之后，标普500指数较9月初创下的历史高点下跌了约4.2%。许多市场人士认为，市场正在经历季节性疲软。\n“过去几周市场情绪似乎发生了有利于空头的变化，”Commonwealth Financial Network投资管理主管Brian Price表示。 “在一个相对平静的夏季之后，市场参与者似乎希望减弱今年的涨势。”\n一些著名的策略师坚持看涨。Fundstrat联合创始人Tom Lee认为，周一股市的暴跌对投资者来说是一个买入机会。摩根大通策略师Marko Kolanovic也称此次抛售过度。\n然而，华尔街最大的空头之一——摩根士丹利的Mike Wilson认为，随着一些经济指标开始恶化，标普500指数将出现20%的回调，这是一种“破坏性”的情景。\n调查结果显示，对于关注收益率的投资者来说，目前最好的策略是私人信贷。只有2%的受访者认为美国国债可以提供有吸引力的收益。\n政府债券正迅速成为最令人厌恶的资产类别之一，因在经济复苏期间其避险吸引力减弱。“老债王”比尔-格罗斯（Bill Gross）近期称美国国债为垃圾，称未来12个月10年期国债收益率将在2%左右，这相当于4%-5%的价格损失和2.5%-3%的负回报。","news_type":1,"symbols_score_info":{"161125":0.9,"513500":0.9,"SPY":0.9,"SSO":0.9,".SPX":0.9,"UPRO":0.9,"ESmain":0.9,"IVV":0.9,"OEF":0.9,"SH":0.9,"SDS":0.9,"SPXU":0.9,"OEX":0.9}},"isVote":1,"tweetType":1,"viewCount":1506,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
